Analysts have refuted Citron Research’s report on Exact Science’s Cologuard, which stated the product was a “seriously inferior product and a disastrous business model.” Despite the report causing Exact Science’s stock to drop 8 percent, analysts still recommend the stock.
Synthetic Biologics’ C. difficile drug, ribaxamase, achieved its primary endpoint in a phase 2b trial. The drug significantly reduces C. difficile infection.
Check-Cap and GE Healthcare achieved their first development milestone when GE’s developed and tested X-rays passed all tests to ensure C-scan system compliance. The companies are working to develop an ingestible capsule that will allow preparation-free colorectal cancer screening.
Takeda Pharmaceuticals’ gastroenterology, oncology and emerging market platforms increased growth by 14.7 percent in fiscal year 2016.
More articles on gastroenterology:
Harrisburg Gastroenterology victim to data breach — 93k records potentially exposed
IBS patients unsatisfied with treatment for factors beyond physician control — 4 study insights
Tofacitinib effective as induction, maintenance therapy in ulcerative colitis treatment — 6 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.